
About
With founders who are global leaders in the structural biology of 14-3-3 proteins and their role in a wide range of protein-protein interactions, our team is developing a new class of medicines that can modulate previously undruggable targets and influence currently accessible ones in new ways. These small molecule stabilizers of 14-3-3:client complexes have the potential to address serious unmet needs in important therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
Our company is committed to aggressively expanding the boundaries of medicine through treatments that modulate some of the most challenging and potentially impactful targets identified across the proteome, with the goal of treating diseases that currently lack a cure and helping patients live longer and healthier lives.

Michelle Arkin, Ph.D.
Co-founder

Tim van der Hek
Research Associate, Biochemistry

Zhen Zhang, Ph.D.
Director, Cancer Biology

Galen Miley, Ph.D.
Scientist, Chemistry

Loes Stevers, Ph.D.
Senior Scientist, Biochemistry

Laura Demmers, Ph.D.
Scientist, Proteomics

Eline Sijbesma, Ph.D.
Scientist, Biochemistry

Fabian Zweipfennig
Research Associate, Structural Biology

Michelle Howarth, Ph.D.
Senior Scientist, Cancer Biology

Mohammed Jalalirad, Ph.D.
Scientist, Cancer Biology

William Goodheart
Associate Scientist, Cancer Biology

Luc Brunsveld, Ph.D.
Co-founder

Rens de Vries, Ph.D.
Scientist, Structural Biology
Investors





